Exploring Immunotherapy Combinations in Endometrial Cancer

Shannon N. Westin, MD, MPH, FACOG, discusses the rationale for the use of combination immunotherapy for advanced and recurrent endometrial cancer.

Vicky Makker, MD, reviews the trial design and efficacy data for the open-label, randomized phase 3 KEYNOTE-775/Study 309 in patients with advanced endometrial cancer.

Vicky Makker, MD, reviews the safety profile of lenvatinib-pembrolizumab in advanced endometrial cancer from the phase 3 KEYNOTE-775/Study 309 trial and the management of common adverse events.

Vicky Makker, MD, and Shannon N. Westin, MD, MPH, FACOG, discuss their experiences using lenvatinib-pembrolizumab therapy for advanced endometrial cancer.

Experts in gynecologic oncology share insights on patient selection for lenvatinib-pembrolizumab in advanced endometrial cancer and discuss therapeutic sequencing through multiple lines of therapy.

Shannon N. Westin, MD, MPH, FACOG, and Vicky Makker, MD, comment on data from ongoing clinical trials presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer for the management of advanced endometrial cancer.

Experts in gynecologic oncology discuss novel combination strategies for the treatment of advanced endometrial cancer.